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MaOBJECTIVES This study sought to evaluate in-hospital outcomes and 3-year mortality of patients presenting with
unprotected left main stem occlusion (ULMSO) treated with primary percutaneous coronary intervention (PPCI).
BACKGROUND Limited data exists about management and outcome following presentation with ULMSO.
METHODS From January 1, 2007 to December 21, 2012, 446,257 PCI cases were recorded in the British Cardiovascular
Intervention Society database of all PCI cases in England and Wales. Of those, 568 were patients having emergency PCI
for ST-segment elevation infarction (0.6% of all PPCI) who presented with ULMSO (TIMI [Thrombolysis In Myocardial
Infarction] ﬂow grade 0/1 and stenosis >75%), and they were compared with 1,045 emergency patients treated with
nonocclusive LMS disease. Follow-up was obtained through linkage with the Ofﬁce of National Statistics.
RESULTS Presentation with ULMSO, compared with nonocclusive LMS disease, was associated with a doubling in the
likelihood of periprocedural shock (57.9% vs. 27.9%; p < 0.001) and/or intra-aortic balloon pump support (52.5% vs.
27.2%; p < 0.001). In-hospital (43.3% vs. 20.6%; p< 0.001), 1-year (52.8% vs. 32.4%; p< 0.001), and 3-year mortality
(73.9% vs 52.3%, p < 0.001) rates were higher in patients with ULMSO, compared with patients presenting with a patent
LMS, and were signiﬁcantly inﬂuenced by the presence of cardiogenic shock. ULMSO and cardiogenic shock were inde-
pendent predictors of 30-day (hazard ratio [HR]: 1.61 [95% conﬁdence interval (CI): 1.07 to 2.41], p ¼ 0.02, and HR: 5.43
[95% CI: 3.23 to 9.12], p<0.001, respectively) and 3-year all-cause mortality (HR: 1.52 [95% CI: 1.06 to 2.17], p ¼ 0.02,
and HR: 2.98 [95% CI: 1.99 to 4.49], p < 0.001, respectively).
CONCLUSIONS In patients undergoing PPCI for ULMSO, acute outcomes are poor and additional therapies are required
to improve outcome. However, long-term outcomes for survivors of ULMSO are encouraging. (J Am Coll Cardiol Intv
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ABBR EV I A T I ON S
AND ACRONYMS
BCIS = British Cardiovascular
Intervention Society
CABG = coronary artery bypass
graft
CI = conﬁdence interval
GP = glycoprotein
HR = hazard ratio
IABP = intra-aortic balloon
pump
IQR = interquartile range
LMS = left main stem
LV = left ventricle
MACCE = major adverse
cardiac and cerebrovascular
events
MI = myocardial infarction
PCI = percutaneous coronary
intervention
PPCI = primary percutaneous
coronary intervention
TIMI = Thrombolysis In
Myocardial Infarction
ULMSO = unprotected left
main stem occlusion
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970coronary intervention (PPCI) for acute MI,
several small registries have investigated
outcomes of patients undergoing emergency
PPCI to left main stem (LMS) disease (2).
However, only sporadic individual cases
(3–7) and 5 small series (cumulatively n ¼
112) (8–12) have reported outcomes of pa-
tients suffering from occlusive or subocclu-
sive LMS disease (8–12) from which there is
limited 1-year mortality data available (total
n ¼ 100) (8,10–12).
These small studies, from several different
populations, suggest that survival is poor
(8–14); however, reliable contemporary in-
formation has not been collated previously,
and this group has not been compared with
outcomes from other emergency patients
with MI. Given the paucity of data, manage-
ment of this potentially catastrophic presen-
tation poses a very signiﬁcant challenge. We
interrogated data from the British Cardio-
vascular Intervention Society’s (BCIS) na-
tional PCI audit with case-based mortality
tracking for 3 years following intervention.
Using these data, we hoped to inform clinical
decision making in the absence of existing
guidelines for emergency treatment.METHODS
DATA SOURCE. The BCIS national audit of PCI is a
prospective registry of all coronary intervention pre-
formed in all interventional cardiology units within
the United Kingdom since 2005 (117 institutions in
2011) (15). A total of 113 ﬁelds of clinical, procedural,
and outcome data are collected (Online Appendix)
centrally at the National Institute for Cardiovascular
Outcomes Research at University College London (15).
All-cause mortality data of the audit cohort in En-
gland and Wales is tracked by the Ofﬁce of National
Statistics.
DATA QUALITY. The completeness and internal con-
sistency of the data are assessed during submission
by a set of validation rules (Online Appendix). If a
major error is detected that might cause the upload to
contaminate the reliability of the complete dataset,
then the record is rejected for resubmission. Less
serious inconsistencies are accepted, but an error log
documents fatal and serious errors, allowing units to
clean and correct their data locally.
STUDY POPULATION. There were 446,257 PCI re-
cords generated in England and Wales between
January 1, 2007, and December 31, 2012. There were105,216 procedures performed as an emergency
(deﬁned as treatment with primary PCI) on 102,057
patients. There were 2,125 patients identiﬁed as
having undergone unprotected LMS PPCI (Figure 1).
This included patients in whom the LMS was treated
in isolation or in combination with other vessels.
From the unprotected LMS PPCI cohort, information
on TIMI (Thrombolysis In Myocardial Infarction) ﬂow
grade and lesion severity was available in 1,613 pa-
tients. There were 568 patients who presented
with ULMSO (deﬁned as pre-procedural LMS stenosis
$75% and TIMI ﬂow grade #1) and who were
compared with 1,045 patients with nonocclusive pre-
procedural LMS disease (deﬁned as LMS stenosis
<75% and/or TIMI ﬂow grade $2). Patient groups
were also divided based on the presence and absence
of periprocedural cardiogenic shock.
CLINICAL ENDPOINTS AND DEFINITIONS. We report the
following: 1) demographic, clinical, and procedural
characteristics of patients with ULMSO; 2) 3-year all-
cause mortality of the patients presenting with
ULMSO stratiﬁed by the presence and absence of
shock; 3) in-hospital rates of major adverse cardiac
and cerebrovascular events (MACCE) deﬁned as
an accumulative composite of death, reinfarction or
reintervention, in-hospital coronary artery bypass
graft (CABG) and cerebrovascular events. Addition-
ally, we aim to determine those factors that predict
short- and long-term mortality.
STATISTICAL ANALYSIS. Normally distributed con-
tinuous variables (e.g., age and body mass index) are
presented as mean  SD and were analyzed using the
independent samples Student t test. Skewed contin-
uous variables (e.g., length of stay) are presented as
median (interquartile range) and were analyzed using
the Mann-Whitney U test. Categorical data are pre-
sented as counts and proportions of valid cases from
the database, and statistical comparisons were made
using the chi-square statistic. All-cause mortality
rates are presented as counts and percentages and as
mortality plots with the number of subjects known to
be at risk at each successive time point. Group dif-
ferences are assessed using the log-rank test. A
landmark analysis was then performed for 30-day and
1-year survivors. A multivariable Cox proportional
hazards regression model was used to estimate the
independent predictors of 30-day and 3-year mortal-
ity. Sequential univariate models were performed
for biologically and clinically relevant covariates
(age; sex; cardiovascular risk factors; renal dys-
function; history of previous MI, PCI, or CABG;
symptom to balloon time; recent lysis; left ventricular
[LV] dysfunction; periprocedural cardiogenic shock;
FIGURE 1 Selection of Investigation Groups
The method of investigation and comparator group selection is demonstrated. IRA ¼ infarct related artery; LMS ¼ left main stem; PCI ¼
percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction; ULMSO ¼ unprotected left main stem occlusion.
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971occlusive LMS disease; multivessel disease; intra-
aortic balloon pump support; glycoprotein (GP) IIb/
IIIa inhibitor use; thrombus aspiration use; and the
presence of post-procedural no-reﬂow). Covariates
with a p value of <0.05 at univariate analysis were
entered into a ﬁnal model using a forward stepwise
method. Proportional hazards assumptions were
evaluated and met for both outcomes and hazard
ratios (HR) are presented as HR (95% conﬁdence
interval [CI]). All p values are 2-sided, and a p value
of <0.05 was considered to be statistically signiﬁcant.
All analyses were conducted in SPSS (version 20,
SPSS, Inc., Chicago, Illinois).RESULTS
During the investigation period, in England and
Wales, 102,057 patients presented for emergency
PPCI with a 30-day mortality of 5.9%. The absolute
annual number of PPCI cases increased from 8,712 in
2007 to 23,632 in 2012, as did the proportion of PPCI
relative to all interventions during the study period
(8.7% to 23.6% per year). The rate of unprotected LMS
PPCI also increased as a proportion of all PPCI from
2.0% to 2.2% per year. A total of 2,125 patients
undergoing unprotected LMS PPCI were identiﬁed
(2.1%). This cohort was compared with 97,974patients undergoing non-LMS emergency PPCI. The
568 patients (0.6% of all PPCI) with ULMSO under-
going PPCI were then compared with the other 1,045
emergency PPCI patients with nonocclusive LMS
disease.
BASE L I N E DEMOGRAPH I C AND CL I N I CAL
CHARACTER I S T I C S . Baseline demographic and
clinical data for patients within the investigation co-
horts are presented in Table 1. Patients undergoing
PPCI treatment for unprotected LMS disease, when
compared with those presenting with non-LMS MI,
were >5 years older, more frequently women, and
more likely to have traditional risk factors of coronary
artery disease such as current smoking, diabetes,
hypertension, hypercholesterolemia, and/or renal
dysfunction (Table 1). Apart from hypertensive status
and history of previous PCI, patients with ULMSO
were well matched with those with nonocclusive LMS
disease for age, sex, and cardiovascular risk factors
(Table 1). The ULMSO group had a higher frequency of
presentation with LV dysfunction (85.6% vs. 68.2%;
p < 0.001) and was approximately twice as likely to
present with periprocedural cardiogenic shock (57.9%
vs. 27.9%; p < 0.001). The median symptom to PCI
hospital and symptom to balloon intervals were
signiﬁcantly shorter in the ULMSO patients than they
were in nonocclusive LMS disease patients (median:









(n ¼ 97,974) p Value
Demographics
Age, yrs 67.92  13.49 69.16  12.81 0.07 69.20  12.96 63.35  13.01 <0.001
Male 424/567 (74.9) 734/1,043 (70.4) 0.06 1,523/2,121 (71.8) 72,769/97,643 (74.5) 0.004
Caucasian 432/467 (92.5) 693/796 (87.1) 0.02 1,454/1,638 (88.8) 68,668/78,849 (87.1) 0.14
Risk factors
Smoking status
Never 158/454 (34.8) 319/897 (35.6) 0.06 604/1,740 (34.7) 27,942/86,466 (32.3) <0.001
Ex-smoker 148/454 (32.6) 337/897 (37.6) 650/1,740 (37.4) 24,013/86,466 (27.8)
Current 148/454 (32.6) 241/897 (26.8) 486/1,740 (27.9) 34,511/86,466 (39.9)
Diabetes 100/522 (19.2) 210/999 (21.0) 0.39 415/1,988 (20.9) 13,131/93,625 (14.0) <0.001
Hypertension 240/514 (46.7) 521/970 (53.7) 0.01 1,019/1,964 (51.9) 39,024/93,267 (41.8) <0.001
Hypercholesterolemia 229/514 (44.5) 467/970 (48.1) 0.19 933/1,964 (47.5) 38,746/93,267 (41.5) <0.001
Previous MI 84/518 (16.2) 253/976 (25.9) <0.001 457/1,871 (24.4) 12,730/89,321 (14.2) <0.001
BMI, kg/m2 26.70  4.84 26.64  4.96 0.88 26.68  4.92 27.51  5.01 <0.001
Family history of CAD 133/432 (30.8) 302/851 (35.5) 0.10 563/1,638 (34.4) 31,614/82,165 (38.5) 0.001
Other history
Previous PCI 39/545 (7.1) 144/1,007 (14.3) <0.001 251/2,029 (12.4) 8,521/94,359 (9.0) <0.001
Previous CABG 10/553 (1.8) 33/1,013 (3.3) 0.09 64/2,039 (3.1) 2,790/93,758 (3.0) 0.67
Renal dysfunction 20/487 (4.1) 46/956 (4.8) 0.54 107/1,916 (5.6) 1,467/90,377 (1.6) <0.001
Previous CVA 31/514 (6.0) 68/970 (7.0) 0.47 143/1,964 (7.3) 3,309/93,267 (3.5) <0.001
Peripheral vascular disease 44/514 (8.6) 110/970 (11.3) 0.09 228/1,964 (11.6) 3,143/93,267 (3.4) <0.001
Pre-procedural antithrombotics
Aspirin 458/533 (85.9) 851/980 (86.8) 0.62 1,616/1,968 (82.1) 74,020/91,127 (81.2) 0.32
Ticlopidine 1/533 (0.2) 4/980 (0.4) 0.47 8/1,968 (0.4) 303/91,127 (0.3) 0.57
Clopidogrel 323/533 (60.6) 679/980 (69.3) 0.001 1,277/1,968 (64.9) 57,334/91,127 (62.9) 0.07
Prasugrel 72/533 (13.5) 104/980 (10.6) 0.09 198/1,968 (10.1) 11,324/91,127 (12.4) 0.002
Ticagrelor 34/533 (6.4) 92/980 (9.4) 0.04 154/1,968 (7.8) 6,333/91,127 (6.9) 0.13
Warfarin 4/533 (0.7) 8/980 (0.8) 0.89 18/1,968 (0.9) 707/91,127 (0.8) 0.49
Recent lysis 34/554 (6.1) 60/942 (6.4) 0.86 104/1,852 (5.6) 7,413/87,649 (8.4) <0.001
Presentation
Symptom to PCI hospital, h 2.13 (1.28–4.19) 2.62 (1.42–6.00) 0.001 2.50 (1.38–5.70) 2.50 (1.50–5.17) 0.78
Symptom to balloon, h 3.27 (2.17–5.58) 3.89 (2.42–7.50) <0.001 3.70 (2.38–6.94) 3.50 (2.33–6.60) 0.06
ECG
ST-segment elevation/LBBB 482/547 (88.1) 682/951 (71.7) <0.001 1,299/1,796 (72.3) 76,662/85,336 (89.8) <0.001
ST-segment depression 34/547 (6.2) 164/951 (17.2) 321/1,796 (17.9) 3,327/85,336 (3.9)
Others 31/547 (5.7) 105/951 (11.1) 176/1,796 (9.8) 5,374/85,336 (6.3)
LV dysfunction 203/237 (85.6) 337/494 (68.2) <0.001 709/961 (73.8) 14,542/31,171 (46.6) <0.001
LV ejection fraction 28.11  13.44 41.46  15.56 <0.001 37.70  15.32 48.03  12.62 <0.001
Periprocedural cardiogenic shock 329/568 (57.9) 290/1,038 (27.9) <0.001 804/2,103 (38.2) 5,737/96,770 (5.9) <0.001
Values are mean  SD, n/N (%), or median (interquartile range). Data are presented as a percentage of the available sample. Data and p values are shown for ULMSO PPCI versus nonocclusive unprotected
LMS PPCI groups and for all unprotected LMS PPCI versus non-LMS PPCI groups. Bold p values refer to the difference in portions of the subgroups.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CVA ¼ cerebrovascular accident/event; ECG ¼ electrocardiogram; LBBB ¼ left bundle branch block; LMS ¼
left main stem; LV ¼ left ventricular; MI ¼ myocardial infarction; PPCI ¼ primary percutaneous coronary intervention; ULMSO ¼ unprotected left main stem occlusion.
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9722.1 [interquartile range (IQR): 1.3 to 4.2] vs. 2.6 [IQR:
1.4 to 6.0] h, p ¼ 0.001, and median: 3.3 [IQR: 2.2 to
5.6] vs. 3.9 [IQR 2.4 to 7.5] h, p < 0.001, respectively).
PROCEDURAL CHARACTERISTICS AND OUTCOMES.
Patients presenting for unprotected LMS PPCI,
compared with the non-LMS PPCI cohort, had a
higher frequency of femoral access use (68.4% vs.
53.7%; p < 0.001) and multivessel intervention
(2.02  0.88 vs. 1.10  0.37; p < 0.001) (Table 2).Additionally, they more frequently required the use
of mechanical ventilation (16.7% vs. 3.5%, respec-
tively; p < 0.001) and circulatory support (57.1% vs.
7.1% respectively; p < 0.001). Following intervention,
the median length of in-patient hospital stay was
signiﬁcantly longer for those having unprotected
LMS PPCI (4.05 [IQR: 2.0 to 8.6] vs. 2.4 [IQR: 1.5 to
3.6] days; p < 0.001). In keeping with the higher rates
of LV dysfunction and cardiogenic shock in the
ULMSO group, the need for mechanical ventilation









(n ¼ 97,974) p Value
Procedural characteristics
Femoral access 411/555 (74.0) 626/1,020 (61.4) <0.001 1,416/2,071 (68.4) 51,382/95,745 (53.7) <0.001
Radial access 188/555 (33.9) 461/1,020 (45.2) <0.001 790/1,443 (54.7) 46,305/95,745 (48.4) <0.001
Mechanical ventilation 128/551 (23.2) 124/991 (12.5) <0.001 312/1,869 (16.7) 2,989/85,695 (3.5) <0.001
Circulatory support
Inotropes 152/556 (27.3) 110/996 (11.0) <0.001 312/1,965 (15.9) 1,783/91,113 (1.9) <0.001
IABP 292/556 (52.5) 271/996 (27.2) <0.001 715/1,965 (36.4) 4,209/91,113 (4.6) <0.001
CPS 34/556 (6.1) 15/996 (1.5) <0.001 59/1,965 (3.0) 236/91,113 (0.3) <0.001
Others 19/556 (3.4) 11/996 (1.1) 0.002 36/1,965 (1.8) 199/91,113 (0.2) <0.001
GP IIb/IIIa inhibitor use 361/548 (65.9) 570/990 (57.6) 0.001 1,147/2,007 (57.1) 50,267/92,536 (54.3) 0.01
Abciximab 296/548 (54.0) 420/990 (42.4) <0.001 869/2,007 (43.3) 39,636/92,536 (42.8) 0.68
Tiroﬁban 22/548 (4.0) 66/990 (6.7) 0.03 113/2,007 (5.6) 2,528/92,536 (2.7) <0.001
Eptiﬁbatide 34/548 (6.2) 66/990 (6.7) 0.72 138/2,007 (6.9) 5,582/92,536 (6.0) 0.12
Heparin 140/187 (74.9) 271/348 (77.9) 0.43 521/655 (79.5) 19,919/28,468 (70.0) <0.001
Also given GP IIb/IIIa inhibitor 98/181 (54.1) 155/326 (47.5) 0.15 307/619 (49.6) 11,654/27,174 (42.9) 0.001
Bivalirudin 33/187 (17.6) 57/348 (16.4) 0.71 99/655 (15.1) 6,668/28,468 (23.4) <0.001
Also given GP IIb/IIIa inhibitor 15/181 (8.3) 19/326 (5.8) 0.29 39/619 (6.3) 1,674/27,174 (6.2) 0.89
Heparin þ bivalirudin 14/187 (7.5) 20/348 (5.8) 0.50 35/655 (5.3) 1,881/28,468 (6.6) 0.22
Also given GP IIb/IIIa inhibitor 6/181 (3.3) 6/326 (1.8) 0.29 12/619 (1.9) 589/27,174 (2.8) 0.70
Aspiration catheter use 215/556 (38.7) 234/1,018 (23.0) <0.001 523/1,969 (26.6) 39,604/92,618 (42.8) <0.001
Embolic protection devices use 3/553 (0.5) 2/1,004 (0.2) 0.25 7/1,943 (0.4) 710/90,195 (0.8) 0.03
Vessels attempted, n 2.02  0.87 2.07  0.86 0.26 2.02  0.88 1.10  0.37 <0.001
Lesions attempted, n 2.03  0.99 2.07  0.97 0.47 2.05  1.00 1.27  0.59 <0.001
Stents, n 1.95  1.38 2.15  1.32 0.005 2.06  1.33 1.40  0.87 <0.001
DES used, n 1.25  1.39 1.50  1.37 0.001 1.40  1.38 0.86  0.97 <0.001
Largest balloon/stent diameter, mm 3.63  0.64 3.84  0.64 <0.001 3.78  0.65 3.32  0.59 <0.001
Longest stented/treated segment, mm 26.68  14.16 26.33  15.47 0.67 26.06  14.79 24.58  12.43 <0.001
IVUS use 60/547 (11.0) 208/1,003 (20.7) <0.001 326/1,937 (16.8) 1,822/89,206 (2.0) <0.001
Rotational, % 4/544 (0.7) 18/989 (1.8) 0.08 36/1,923 (1.9) 119/89,936 (0.1) <0.001
Cutting balloon, % 18/544 (3.3) 34/989 (3.4) 0.89 67/1,923 (3.5) 2,818/89,936 (3.1) 0.38
Procedural outcomes
Lesion success 1.82  1.07 1.95  0.99 0.02 1.88  1.04 1.20  0.59 <0.001
TIMI ﬂow grade
0 56/539 (10.4) 38/910 (4.2) <0.001 109/1,650 (6.6) 4,649/79,890 (5.8) <0.001
1 27/539 (5.0) 13/910 (1.4) 45/1,650 (2.7) 1,021/79,890 (1.3)
2 67/539 (12.4) 56/910 (6.1) 145/1,650 (8.8) 4,076/79,890 (5.1)
3 389/539 (72.2) 803/910 (88.3) 1,351/1,650 (81.9) 70,144/79,890 (87.8)
Side branch occlusion 4/387 (1.0) 16/827 (1.9) 0.25 25/1,511 (1.6) 493/82,137 (0.6) <0.001
Coronary dissection 21/404 (5.2) 79/891 (8.9) 0.02 119/1,606 (7.4) 1,242/82,871 (1.5) <0.001
Aortic dissection 2/386 (0.5) 6/819 (0.7) 0.67 8/1,497 (0.5) 52/81,704 (0.1) <0.001
Coronary perforation 2/386 (0.5) 9/822 (1.1) 0.32 11/1,500 (0.7) 239/81,889 (0.3) 0.002
Tamponade 2/550 (0.4) 2/1,011 (0.2) 0.54 4/2,060 (0.2) 106/95,081 (0.1) 0.27
Intubation/ventilation 49/433 (11.3) 30/843 (3.5) <0.001 112/1,601 (7.0) 469/82,105 (0.6) <0.001
Shock induced by procedure 25/462 (5.4) 29/871 (3.3) 0.07 78/1,662 (4.7) 509/83,854 (0.6) <0.001
Pacing for heart block 20/404 (4.9) 15/828 (1.8) 0.002 44/1,533 (2.9) 633/82,265 (0.8) <0.001
No-ﬂow/slow reﬂow 31/414 (7.5) 26/839 (3.1) <0.001 71/1,559 (4.5) 2,119/83,754 (2.5) <0.001
Nonaccess site–related bleeding 20/550 (3.6) 25/1,011 (2.5) 0.19 52/2,060 (2.5) 725/95,081 (0.8) <0.001
Arterial complications 26/530 (4.9) 47/984 (4.8) 0.91 83/1,932 (4.3) 1,417/89,864 (1.6) <0.001
Renal failure/dialysis 6/550 (1.1) 8/1,011 (0.8) 0.55 20/2,060 (1.0) 255/95,081 (0.3) <0.001
Length of hospital stay, days 4.53 (2.10–10.44) 3.60 (1.96–7.54) 0.03 4.05 (2.03–8.60) 2.37 (1.50–3.55) <0.001
Values are n/N (%), mean  SD, or median (interquartile range). Data are presented as a percentage of the available sample. Data and p values are shown for ULMSO PPCI versus nonocclusive unprotected
LMS PPCI groups and for all unprotected LMS PPCI versus non-LMS PPCI groups. Bold p values refer to the difference in portions of the subgroups.
CPS ¼ cardiopulmonary support; DES ¼ drug-eluting stents; GP ¼ glycoprotein; IABP ¼ intra-aortic balloon pump; IVUS ¼ intravascular ultrasound; TIMI ¼ Thrombolysis In Myocardial Infarction; other
abbreviations as in Table 1.
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(n ¼ 97,974) p Value
In hospital MACCE 246/568 (43.3) 219/1,045 (20.6) <0.001 586/2,125 (27.6) 5,246/97,974 (5.3) <0.001
In-hospital death 232/558 (41.6) 195/1,009 (19.3) <0.001 540/2,064 (26.2) 3,907/96,249 (4.0) <0.001
Nonfatal MI or reintervention 7/550 (1.3) 13/1,011 (1.3) 0.98 21/2,060 (1.0) 697/95,081 (0.7) 0.13
Urgent or emergency CABG 9/549 (1.6) 19/1,007 (1.9) 0.73 38/2,053 (1.8) 647/94,940 (0.7) <0.001
Embolic CVA 2/535 (0.4) 4/992 (0.4) 0.93 8/2,018 (0.4) 206/93,885 (0.2) 0.09
1-year mortality 273/517 (52.8) 289/902 (32.0) <0.001 739/1,857 (39.8) 8,174/83,853 (9.7) <0.001
With periprocedural CS 217/304 (71.4) 165/262 (63.0) 0.03 482/739 (65.2) 2,282/5,161 (44.2) <0.001
Without periprocedural CS 56/213 (26.3) 124/640 (19.4) 0.03 257/1,118 (23.0) 5,892/78,692 (7.5) <0.001
3-year mortality 295/399 (73.9) 333/637 (52.3) <0.001 837/1,386 (60.4) 10,981/52,966 (20.7) <0.001
With periprocedural CS 223/259 (86.1) 175/221 (79.2) 0.04 507/628 (80.7) 2,458/4,005 (61.4) <0.001
Without periprocedural CS 72/140 (51.4) 158/416 (37.7) 0.005 330/758 (43.5) 8,523/48,961 (17.4) <0.001
Values are n/N (%). Data are presented as a percentage of the available sample. Data and p values are shown for ULMSO PPCI versus nonocclusive unprotected LMS PPCI groups and for all
unprotected LMS PPCI versus non-LMS PPCI groups.
CS ¼ cardiogenic shock; MACCE ¼ major adverse cardiovascular and cerebrovascular events; other abbreviations as in Table 1.
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974(23.2% vs. 12.5% respectively; p < 0.001) and circu-
latory support (87.5% vs. 40.9% respectively; p <
0.001) were signiﬁcantly higher than for the non-
occlusive LMS PPCI group. Furthermore, intervention
was approximately 2 more likely to end with ﬁnal
no-reﬂow or slow ﬂow in the ULMSO PPCI group than
in the nonocclusive LMS PPCI group (7.5% vs. 3.1%,
respectively; p < 0.001). The use of an aspiration
catheter was signiﬁcantly higher in the ULMSO PPCI
group (38.7% vs. 23.0%, respectively; p < 0.001),
whereas intravascular ultrasound utilization was
one-half of that seen in the nonocclusive LMS PPCI
group (11.0% vs. 20.7%, respectively; p < 0.001).
IN-HOSPITAL CLINICAL OUTCOMES. Of all patients
having unprotected LMS PPCI, the in-hospital mor-
tality was more than 6-fold higher than that of the
non-LMS PPCI cohort (26.2% vs. 4.1%, respectively;
p < 0.001) (Table 3). Patients with ULMSO had
in-hospital MACCE (43.3% vs. 20.6%; p < 0.001) and
mortality rates (41.6% vs. 19.3%; p < 0.001) that
were approximately 2 higher than those for
patients with nonocclusive LMS disease. In all
groups, the in-hospital MACCE rate was principally
driven by in-hospital mortality (Table 3). In the
ULMSO group, 9 patients (1.6%) underwent urgent
or emergency CABG, 7 patients suffered nonfatal MI
or underwent reintervention, and a further 2 pa-
tients had embolic strokes. Additionally, 30.6% (174)
of all ULSMO patients were treated in PCI centers
without on-site surgical cover. This was associated
with a slightly higher, but not statistically signiﬁ-
cant, increase in in-hospital mortality (46.2% vs.
39.6%; p ¼ 0.15).CLINICAL FOLLOW-UP. The 1-year and 3-year all-
cause mortality rates for patients undergoing unpro-
tected LMS PPCI were 39.8% and 60.4%, respectively,
compared with 9.8% and 20.7%, respectively, in those
having non-LMS PPCI (p < 0.001) (Table 3). Mortality
at both 1 and 3 years was adversely affected by the
presence of periprocedural shock by approximately a
factor of 2 in the unprotected LMS PPCI group
(cardiogenic shock: 65.2% vs. no cardiogenic shock:
23.0%; p < 0.001 at 1 year; and cardiogenic shock:
80.7% vs. no cardiogenic shock: 43.5%; p < 0.001 at 3
years) and by a factor of >3 in the non-LMS PPCI
group at 3 years (cardiogenic shock: 44.2% vs. no
cardiogenic shock: 7.5%; p < 0.001 at 1 year; and
cardiogenic shock: 61.4% vs. no cardiogenic shock:
17.4%; p < 0.001 at 3 years). The mortality plot in
Figure 2A shows the mortality rate at 3-year follow-up
for unprotected LMS PPCI and non-LMS PPCI groups
stratiﬁed by the presence and absence of periproce-
dural cardiogenic shock and conﬁrms a higher mor-
tality in patients admitted with cardiogenic shock.
Furthermore, the need for unprotected LMS inter-
vention confers a further mortality risk irrespective
of the presence or absence of cardiogenic shock
(p < 0.001).
A similar trend was observed for 1- and 3-year all-
cause mortality for patients undergoing ULMSO
PPCI versus those having nonocclusive LMS PPCI
(52.8% vs. 32.0%, p < 0.001 at 1 year; and 73.9% vs.
52.3%, p < 0.001 at 3 years). Furthermore, mortality at
both 1 and 3 years were adversely affected by the
presence of periprocedural shock in the ULMSO PPCI
group (cardiogenic shock: 71.4% vs. no cardiogenic
shock: 26.3%; p < 0.001 at 1 year; and cardiogenic
FIGURE 2 Plots of Mortality of Patients Undergoing PPCI Stratiﬁed by Periprocedural CS
Mortality plots to 3 years of patients undergoing unprotected LMS versus non-LMS primary PCI (A) and patients undergoing unprotected LMS
occlusion versus nonocclusive LMS primary PCI (B), separated by the presence or absence of periprocedural cardiogenic shock. CS ¼ cardiogenic
shock; IABP ¼ intra-aortic balloon pump; PPCI ¼ primary percutaneous coronary intervention; other abbreviations as in Figure 1.
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975shock: 86.1% vs. no cardiogenic shock: 51.4%;
p < 0.001 at 3 years), and this affect was more pro-
nounced in the nonocclusive LMS PPCI group
(cardiogenic shock: 63.0% vs. no cardiogenic shock:
19.4%; p < 0.001 at 1 year; and cardiogenic shock:
79.2% vs. no cardiogenic shock: 37.7%; p < 0.001 at
3 years). Mortality plots in Figure 2B show the 3-year
all-cause mortality in the ULMSO PPCI and non-
occlusive LMS PPCI cohorts stratiﬁed by the presence
and absence of periprocedural cardiogenic shock and
conﬁrms a higher mortality observed in patients
admitted with cardiogenic shock and with a further
adverse effect on mortality conferred by occlusive
disease (p < 0.001). Furthermore, within the ULMSO
cohort, there is a mortality beneﬁt associated with
intra-aortic balloon pump (IABP) use in those with
periprocedural cardiogenic shock at 3 years (83.6% vs.
90.8%; p < 0.001) (Figure 3). In the absence of
periprocedural cardiogenic shock, in this group, IABP
use had a marginally lower mortality rate than for
those in whom IABP was not used, but this difference
was not statistically signiﬁcant (53.1% vs. 48.8%;
p ¼ 0.47).
The use of aspiration catheters in those with ULMSO
was not associated with a mortality beneﬁt at 3 years
(74.5% vs. 73.4%; p ¼ 0.92); however, patients
receiving GP IIb/IIIa inhibitors had a lower mortality
rate than did those patients who were not treated with
GP IIb/IIIa inhibitors (66.9% vs. 85.6%; p < 0.001).Notably, mortality rates diverge early depending on
LMS occlusion and cardiogenic shock status, and at 30
days, mortality rates are markedly discordant be-
tween the 4 subgroups (log rank p < 0.001) (Figure 4A).
A signiﬁcantly higher mortality was detected at 30
days in patients with ULMSO presenting with cardio-
genic shock (74.8%) than in those with nonocclusive
LMS PPCI with cardiogenic shock (63.8%), compared
with those with UMLSO without cardiogenic shock
(32.9%) and those with nonocclusive LMS PPCI
without cardiogenic shock (19.0%). Landmark anal-
ysis of 30-day survivors, demonstrated a higher mor-
tality in patients with cardiogenic shock on admission
(32.4% vs. 12.8%, log rank p < 0.001) irrespective of
the presence or absence of occlusive LMS disease
(Figure 4B). Conversely, landmark analysis of 1-year
survivors demonstrated similar mortality rates up to
3-year follow-up in all 4 subgroups (log rank p ¼ 0.29)
(Figure 4C).
INDEPENDENT PREDICTORS OF 30-DAY AND 3-YEAR
MORTALITY. Multivariable Cox proportional hazards
regression modeling showed that the following fac-
tors were independent predictors of 30-day mortality
in those undergoing unprotected LMS PPCI: ULMSO
(HR: 1.61 [95% CI: 1.07 to 2.41); p ¼ 0.02); periproce-
dural cardiogenic shock (HR: 5.43 [95% CI: 3.23 to
9.12]; p < 0.001); age (HR: 1.02 [95% CI: 1.01 to 1.03];
p ¼ 0.04); female sex (HR: 0.43 [95% CI: 0.27 to 0.69];
FIGURE 3 Mortality Plot of Patients Undergoing PPCI for ULMSO Stratiﬁed by
Periprocedural CS and Use of IABP
Mortality plots to 3 years. Abbreviations as in Figures 1 and 2.
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976p ¼ 0.001); acute LV dysfunction (HR: 2.37 [95% CI:
1.18 to 4.76]; p ¼ 0.01); GP IIb/IIIa inhibitor use (HR:
0.63 [95% CI: 0.87 to 0.96]; p ¼ 0.03); and post-
procedural no-reﬂow (HR: 4.15 [95% CI: 2.20 to
7.81]; p < 0.001) (Figure 5A). At long-term follow-up
(3 years), UMLSO (HR: 1.52 [95% CI: 1.06 to 2.17]; p ¼
0.02), per-procedural cardiogenic shock (HR: 2.98
[95% CI: 1.99 to 4.49]; p < 0.05 01), age (HR: 1.02 [95%
CI: 1.01 to 1.03]; p ¼ 0.03), female sex (HR: 0.64 [95%
CI: 0.44 to 0.94]; p ¼ 0.02), GP IIb/IIIa use (HR: 0.59
[95% CI: 0.41 to 0.85]; p ¼ 0.004), and occurrence of
post-procedural no-reﬂow (HR: 2.73 [95% CI: 1.56 to
4.79]; p ¼ 0.001) were found to be independent pre-
dictors of mortality (Figure 5B).
DISCUSSION
Emergency presentation with occlusion of the left
main coronary artery is arguably the most dramatic
and catastrophic coronary event. The existing
descriptive literature of patients and outcomes is
limited to small single-center reports (8–12). We report
the ﬁrst data from a comprehensive national registryof patients undergoing ULMSO PPCI. Our data docu-
ments that the incidence of presenting with ULMSO
and undergoing PPCI is 0.6% of all PPCI (approxi-
mately 15 cases/year/100,000 population). Despite
treatment, in-hospital mortality was 42%; 1-year
mortality was 53%; and 3-year mortality was 74%.
The current medical literature of patients pre-
senting with ULMSO is based on approximately 150
cases including those reported as single case reports
(3–12), and outcomes from the largest series are
summarized in Table 4. These historical data can be
contrasted with our presentation of contemporary
and comprehensive U.K. interventional practice. In
our series, almost all patients underwent coronary
stenting (compared with only 56% to 80% of patients
in previous reports [8,10–12]), and approximately
two-thirds of the stents used were drug eluting. Our
study shows that presentation with ULMSO is more
likely in older patients, in patients with peripheral
vascular disease, previous cerebrovascular accident,
and/or renal failure relative to patients undergoing
non-LMS PPCI. The lower prevalence of cardiogenic
shock in our study compared with that of previous
series (57.9%) may explain the lower use of IABP
(52.5%) (8–12), but it may also be related to the
availability of a wider range of other mechanical
hemodynamic support devices (16). Reassuringly, the
in-hospital mortality in our study is lower than that
previously reported (43.3% vs. an average mortality
in previous studies of 54%) (8–12) (Table 4), suggest-
ing perhaps a positive impact on outcomes from
contemporary therapies/strategies. However, 1-year
mortality of this cohort remains comparable to pre-
vious series (52.8% vs. 44% to 70%, respectively)
(8,10–12), as does the mortality in ULMSO PPCI pa-
tients with cardiogenic shock (71.4% vs. 71% to 79%,
respectively), though the historical data are based on
small numbers and subgroup analyses (10,13). To our
knowledge, there are no long-term (3-year) outcome
data for this cohort in the literature.
Our study shows that despite aggressive invasive
treatment in-patient mortality remains very high. This
information is valuable for responsible healthcare
professionals, and patients’ families should be coun-
seled accordingly. However, it is interesting to note
that of 30-day survivors of unprotected LMS PPCI,
mortality differences in the subsequent year appear to
be principally driven by the presence or absence of
cardiogenic shock and not primarily by occlusion sta-
tus. Furthermore, irrespective of shock and occlusion
status, no mortality difference was detected in 1-year
survivors up to 3 years in these 4 subgroups. It is
possible to speculate that this may be related to the
presence of extensive myocardial stunning and
FIGURE 4 Mortality Plot Landmark Analyses of Patients Undergoing PPCI for
ULMSO Versus Nonocclusive LMS Disease Stratiﬁed by Periprocedural CS
(A) The 30-day mortality of patients undergoing primary PCI for unprotected LMS oc-
clusion versus nonocclusive LMS disease divided by the presence or absence of peri-
procedural CS is shown. (B) The mortality plot of 30-day survivors and (C) the mortality of
1-year survivors are shown. Abbreviations as in Figures 1 and 2.
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977ultimately myocardial recovery, which is likely to be
particularly prevalent in this patient group.
There are currently no speciﬁc guidelines for the
management of acute ULMSO. In the absence of any
reports of conservative medical management or trial
data addressing the relative beneﬁt of PCI versus
CABG, we propose that the goals of therapy in the
acute setting are 3-fold. First, we recommend prompt
restoration of left coronary artery myocardial per-
fusion. CABG can be considered (13,17) but the
fulminant presentation of these cases may make it
impractical unless a cardiac theater and its team are
immediately available. There are no comparative
data, and it is unlikely that there will ever be a trial.
Attempting to re-establish epicardial coronary blood
ﬂow by thrombus aspiration is a logical preliminary
step, as this may conﬁrm the anatomy and the loca-
tion of the guidewire. Reconsideration of revascular-
ization options is probably appropriate at this stage as
our study demonstrates that coronary stenting has a
high risk of no-reﬂow, in part due to a relatively large
plaque and/or thrombotic volume (18,19), as well as a
reﬂection of extensive myocardial ischemia and
necrosis. In support of this, we report a detri-
mental effect on long-term survival associated with
no-reﬂow (HR: 2.73; p ¼ 0.001) and evidence of a
mortality beneﬁt associated with the use of GP IIb/IIIa
inhibitors (HR: 0.59; p ¼ 0.004 in those with unpro-
tected LMS; and p < 0.001 in those with ULMSO).
Second, our data emphasize the likelihood of
requiring hemodynamic support during the acute
management of ULMSO in view of a high shock rate
(almost 60%). The majority of previous ULMSO series
report almost universal use of IABP and precede
recent data that have questioned the utility of IABP,
including the IABP-SHOCK II (Intra-Aortic Balloon
Counterpulsation in Acute Myocardial Infarction
Complicated by Cardiogenic Shock) trial (20), which
suggested no beneﬁt in PPCI patients with cardio-
genic shock. However, the BCIS-I (Balloon-Pump
Assisted Coronary Intervention Study) trial (21) did
demonstrate mortality beneﬁt in those with a high
jeopardy score and severe left ventricular dysfunc-
tion undergoing elective PCI. Jeopardy scores conﬁrm
that LMS intervention is associated with a very large
area of myocardium at risk (21–24), and the majority
of the LV is likely to be hibernating/stunned as a
consequence of unprotected LMS occlusion (25). In
our institutional experience of ULMSO (3,4), pulmo-
nary edema may not be present on arrival in hospital,
but it occurs shortly thereafter mandating use of me-
chanical hemodynamic support early during the pro-
cedure. IABP use is recommended by EACTS/ESC (26)
and ACCF/AHA/SCAI guidelines (Class I and Class IIarecommendations, respectively) (27). Our data sup-
ports IABP use in ULMSO, particularly in those with
periprocedural cardiogenic shock. However, this de-
vice does not provide comparable LV support when
compared with newer, more efﬁcient percutaneous
hemodynamic support devices including Impella
(Abiomed, Inc., Danvers, Massachusetts), Tandem-
Heart (CardiacAssist, Inc., Pittsburgh, Pennsylvania),
and extracorporeal membrane oxygenation (28),
which may explain the very high mortality rate
despite IABP’s use and therefore these newer devices
may have an important role in the future. Percuta-
neous techniques to allow rapid establishment of
extracorporeal membrane oxygenation would appear
to be beneﬁcial, but the increase in afterload may
prove to be detrimental to LV function. In principle,
devices such as Impella, which increase cardiac output
without increasing myocardial work (28), might be
more suited for use in this condition, which has a high
initial mortality but a reasonable long-term prognosis.
Third, supplementary inotropic and ventilator
support was required 14- and 6-fold, respectively,
more often in patients with ULMSO than in patients
undergoing non-LMS PPCI. Therefore, we recommend
FIGURE 5 Independent Predictors of 30-Day and 3-Year Mortality of Patients Undergoing PPCI for ULMSO
Forest plots of independent predictors of mortality from a multivariable Cox proportional hazards regression model of patients undergoing PPCI for unprotected LMS
occlusion at 30 days (A) and 3 years (B). CI ¼ conﬁdence interval; GP ¼ glycoprotein; HR ¼ hazard ratio; LV ¼ left ventricular; other abbreviations as in Figures 1 and 2.
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978early/immediate anesthetic support at presentation
not only for help in acute ventilatory/gas exchange
stabilization of the patient, but also for early advice
regarding a coordinated management plan on the
intensive care unit. Cardiogenic shock is common
among patients undergoing ULMSO PPCI, and in this
group, its associated mortality is very high (61.4% in-
hospital mortality). Optimization of treatment on
intensive or coronary care units for such patients is
of paramount importance as death in patients with
cardiogenic shock occurs not only as a consequence
of pump failure, but also as a secondary consequence
to multiorgan failure and systemic inﬂammatory
response syndrome (29,30). Pharmacological ino-
tropes can improve observed hemodynamics, but useeries of Patients Undergoing PPCI on ULMSO (N ¼ 112)
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other abbreviations as in Tables 1 to 3.of these agents should be carefully considered as they
could increase myocardial ischemia and infarct size as
well as having detrimental effects on peripheral organ
perfusion, which may limit long-term survival (16).
STUDY LIMITATIONS. Our study data is from a na-
tional PCI database, and although it has standardized,
validated, and comprehensive data, the limitations of
the retrospective analysis of a registry require
acknowledgment. Additionally, this registry does not
have data pertaining to those that died prior to any
attempted PCI (including those labeled with sudden
cardiac death in the community), or those patients
treated conservatively. There is no data regarding
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979PCI. Therefore, a true representation of the incidence
of this condition cannot be made. Accurate data are
lacking regarding cardiac enzyme titers and other
serological parameters such as creatinine (renal fail-
ure was deﬁned as creatinine >200 mmol/l), and the
database lacks precise anatomical or lesion-speciﬁc
information including lesion site (e.g., involvement
of the primary bifurcation, ostial lesions, SYNTAX
[Synergy Between Percutaneous Coronary Interven-
tion With Taxus and Cardiac Surgery] score) that may
offer insight into outcomes dependent on complexity
of intervention.
CONCLUSIONS
The strongest predictors of 3-yearmortality in patients
undergoing PPCI to an unprotected LMS are peri-
procedural cardiogenic shock, post-procedural no-
reﬂow, and occlusive LMS disease. The in-hospital,
1-year, and 3-year mortality rates for patients pre-
senting to the catheterization laboratory with acute
MI due to ULMSO are 41.6%, 52.8%, and 73.9%,respectively. For those with periprocedural cardio-
genic shock, mortality rates are 61.4%, 71.4%, and
86.1%, respectively. This registry provides a resource
to inform survivors of the long-term outcomes of pa-
tients presenting to the catheterization lab with an
acute MI due to ULMSO and may serve for future
reference to optimize treatment strategies of this
high-risk patient group.
ACKNOWLEDGMENTS The authors would like to
thank the BCIS, the National Institute for Cardiovas-
cular Outcomes Research, and the Ofﬁce of National
Statistics for collecting and sharing the data pre-
sented. Additionally, they acknowledge all the hos-
pitals in England and Wales for their contribution of
data.
REPRINT REQUESTS AND CORRESPONDENCE: Prof.
A.P. Banning, Oxford University Hospitals, Oxford Health
Centre, Cardiology Department, Level 2, John Radcliffe
Hospital, Headley Way, Oxford OX3 9DU, United
Kingdom. E-mail: adrian.banning@ouh.nhs.uk.RE F E RENCE S1. Fabre A, Sheppard MN. Sudden adult death
syndrome and other non-ischaemic causes of
sudden cardiac death. Heart 2006;92:316–20.
2. Vis MM, Beijk MA, Grundeken MJ, et al.
A systematic review and meta-analysis on primary
percutaneous coronary intervention of an unpro-
tected left main coronary artery culprit lesion in
the setting of acute myocardial infarction. J Am
Coll Cardiol Intv 2013;6:317–24.
3. Banning AP. Images in cardiology: primary
angioplasty and stenting of left main coronary
occlusion. Heart 1998;79:528–9.
4. Van Gaal WJ, Jennings BR, Banning AP. Late
adverse ventricular remodelling as a consequence
of acute left main coronary artery occlusion. Heart
2007;93:1019.
5. Aygül N, Aygül MU, Özdemir K, Altunkeser BB.
Emergency revascularization procedures in pa-
tients with acute ST-elevation myocardial infarc-
tion due to acute total occlusion of unprotected
left main coronary artery: a report of ﬁve cases.
Turk Kardiyol Dem Ars 2010;38:131–4.
6. Malekpour F, Castillo R. Surviving a rare event:
left main coronary artery occlusion. Tex Heart Inst
J 2012;39:594–5.
7. Friedenberger J, Thiele H. Survival of acute ST-
elevation myocardial infarction with total occlu-
sion of the left main coronary artery. BMJ Case
Report 2010 Oct 28;2010. pii: bcr120092467.
doi:10.1136/bcr.11.2009.2467.
8. Chia PL, Khoo BC, Ng CK, Lim JT. Primary
percutaneous coronary intervention for acute
myocardial infarction secondary to acute left main
coronary occlusion in an institution withouton-site cardiothoracic surgical support. Euro-
Intervention 2009;4:617–9.
9. Valeur N, Gaster AL, Saunamäki K. Percuta-
neous revascularization in acute myocardial
infarction due to left main stem occlusion.
Scand Cardiovasc J 2005;39:24–9.
10. Sakai K, Nakagawa Y, Kimura T, et al.
Primary angioplasty of unprotected left main
coronary artery for acute anterolateral
myocardial infarction. J Invasive Cardiol 2004;
16:621–5.
11. De Luca G, Suryapranata H, Thomas K, et al.
Outcome in patients treated with primary angio-
plasty for acute myocardial infarction due to left
main coronary artery occlusion. Am J Cardiol
2003;91:235–8.
12. Yip H, Wu C, Chen M, et al. Effect of primary
angioplasty on total or subtotal left main occlu-
sion: analysis of incidence, clinical features, out-
comes, and prognostic determinants. Chest 2001;
120:1212–7.
13. Grundeken MJ, Vis MM, Beijk MA, et al.
Clinical outcomes after percutaneous or surgical
revascularisation of unprotected left main
coronary artery-related acute myocardial infarc-
tion: a single-centre experience. Heart 2013;99:
690–9.
14. Puricel S, Adorjan P, Oberhänsli M, et al.
Clinical outcomes after PCI for acute coronary
syndrome in unprotected left main coronary artery
disease: insights from the Swiss Acute Left Main
Coronary Vessel Percutaneous Management
(SALVage) study. EuroIntervention 2011;7:
697–704.15. Ludman PF. British Cardiovascular Interven-
tion Society Registry for audit and quality
assessment of percutaneous coronary in-
terventions in the United Kingdom. Heart 2011;97:
1293–7.
16. Ouweneel DM, Henriques JP. Percutaneous
cardiac support devices for cardiogenic shock:
current indications and recommendations. Heart
2012;98:1246–54.
17. Montalescot G, Brieger D, Eagle KA, et al., for
the GRACE Investigators. Unprotected left main
revascularization in patients with acute coronary
syndromes. Eur Heart J 2009;30:2308–17.
18. Abbo M, Dooris M, Glazier S, et al. Features
and outcomes of no-reﬂow after percutaneous
coronary intervention. Am J Cardiol 1995;75:
778–82.
19. Tanaka A, Kawarabayashi T, Nishibori Y, et al.
No-reﬂow phenomenon and lesion morphology
in patients with acute myocardial infarction.
Circulation 2002;105:2148–52.
20. Thiele H, Zeymer U, Neumann FJ, et al., for
the IABP-SHOCK II Trial Investigators. Intra-aortic
balloon counterpulsation in acute myocardial
infarction complicated by cardiogenic shock
(IABP-SHOCK II): ﬁnal 12 month results of a
randomised, open-label trial. Lancet 2013;382:
1638–45.
21. Perera D, Stables R, Clayton T, et al., for the
BCIS-1 Investigators. Long-term mortality data
from the balloon pump-assisted coronary inter-
vention study (BCIS-1): a randomized, controlled
trial of elective balloon counterpulsation during
high-risk percutaneous coronary intervention.
Circulation 2013;127:207–12.
Patel et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 9 , 2 0 1 4
Primary PCI of Unprotected LMS Occlusion S E P T E M B E R 2 0 1 4 : 9 6 9 – 8 0
98022. Califf RM, Phillips HR 3rd, Hindman MC, et al.
Prognostic value of a coronary artery jeopardy
score. J Am Coll Cardiol 1985;5:1055–63.
23. Alderman E, Stadius M. The angiographic
deﬁnitions of the bypass angioplasty revasculari-
zation investigation. Coron Artery Dis 1992;3:
1189–207.
24. De Silva K, Morton G, Sicard P, et al. Prog-
nostic utility of BCIS myocardial jeopardy score for
classiﬁcation of coronary disease burden and
completeness of revascularization. Am J Cardiol
2013;111:172–7.
25. Heusch G, Schulz R. Hibernating myocardium:
a review. J Mol Cell Cardiol 1996;28:2359–72.
26. Wijns W, Kolh P, Danchin N, et al., for the Task
Force on Myocardial Revascularization of the
European Society of Cardiology and the EuropeanAssociation for Cardio-Thoracic Surgery, European
Association for Percutaneous Cardiovascular
Interventions. Guidelines on myocardial revascu-
larization. Eur Heart J 2010;31:2501–55.
27. O’Gara PT, Kushner FG, Ascheim DD, et al.
2013 ACCF/AHA guideline for the management of
ST-elevation myocardial infarction: executive
summary: a report of the American College of
Cardiology Foundation/American Heart Associa-
tion Task Force on Practice Guidelines. J Am Coll
Cardiol 2013;61:485–510.
28. Burkhoff D, Naidu SS. The science behind
percutaneous hemodynamic support: a review
and comparison of support strategies. Catheter
Cardiovasc Interv 2012;80:816–29.
29. Prondzinsky R, Lemm H, Swyter M, et al. Intra-
aortic balloon counterpulsation in patients withacute myocardial infarction complicated by
cardiogenic shock: the prospective, randomized
IABP SHOCK Trial for attenuation of multiorgan
dysfunction syndrome. Crit Care Med 2010;38:
152–60.
30. Hochman J. Cardiogenic shock complicating
acute myocardial infarction: expanding the para-
digm. Circulation 2003;107:2998–3002.
KEY WORDS coronary occlusion,
coronary thrombosis, myocardial infarction,
percutaneous coronary intervention, shock
APPENDIX For the supplemental dataset and
validation rules, please see the online version of
this paper.
